Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical United States Drug Approval Standards

FDA Generics Director’s Departure Shows Why Chemistry Matters

  • News

Executive Summary

Another outside candidate is expected to eventually take over for the departing director Gregory Geba, and while the Office of Generic Drugs can run smoothly without a permanent leader for now, it cannot do so forever.

Table

View full table

Advertisement

Related Content

Pink Sheet
FDA’s Generics Office Loses Another Director As Geba Makes Quick Exit
Pink Sheet
CDER Taps Genzyme Exec As Deputy Director For Science Operations
Pink Sheet
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
Pink Sheet
Boehringer Ingelheim’s Me-Too Petition Against Generic Spiriva
Pink Sheet
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
Pink Sheet
Clinical Trials Not Required For Lidoderm Generics, FDA Tells Endo
Pink Sheet
FDA Office Of Generic Drugs Director Has Brand Industry Background
Pink Sheet
FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution
Pink Sheet
FDA's Buehler To Join Teva
Pink Sheet
FDA's Generic Drugs Office Faces Transition As Director Buehler Departs

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical United States Drug Approval Standards
UsernamePublicRestriction

Register

PS055188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By